Back to Browse Journals » Research and Reports in Urology » Volume 3

Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer

Authors Solanki AA, Liauw SL

Published Date June 2011 Volume 2011:3 Pages 95—104

DOI http://dx.doi.org/10.2147/RRU.S14245

Published 15 June 2011

Abhishek A Solanki, Stanley L Liauw
Department of Radiation and Cellular Oncology, University of Chicago Medical Center, Chicago, IL, USA

Abstract: Brachytherapy and external beam radiotherapy are effective and commonly used treatment modalities in men with localized prostate cancer. In this review, we explore the role of radiation therapy in the curative management of prostate cancer, including the use of conformal therapeutic techniques to allow for the escalation of radiation doses to tumor, along with the use of combined radiation and hormonal therapy to enhance disease outcomes in men with aggressive disease. We also review the possible anticancer role of HMG-CoA reductase inhibiting agents (statins) in men with prostate cancer. Laboratory evidence suggests that statins may have antineoplastic effects when used alone and may sensitize cells to radiation therapy when given in combination. We explore the biologic basis for an anticancer effect and the clinical evidence suggesting statins may aid in improving outcomes with radiation therapy for localized prostate cancer.

Keywords:
HMG-CoA reductase inhibitors, statins, radiotherapy, prostate cancer

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Readers of this article also read:

Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR

Richer AL, Friel JM, Carson VM, Inge LJ, Whitsett TG

Pharmacogenomics and Personalized Medicine 2015, 8:63-79

Published Date: 20 February 2015

Global regulatory landscape of biosimilars: emerging and established market perspectives

Krishnan A, Mody R, Malhotra H

Biosimilars 2015, 5:19-32

Published Date: 17 February 2015

Internalization: acute apoptosis of breast cancer cells using herceptin-immobilized gold nanoparticles

Rathinaraj P, Al-Jumaily AM, Huh DS

Breast Cancer: Targets and Therapy 2015, 7:51-58

Published Date: 10 February 2015

Value of portal venous system radiological indices in predicting esophageal varices

Gaduputi V, Patel H, Sakam S, Neshangi S, Ahmed R, Lombino M, Chilimuri S

Clinical and Experimental Gastroenterology 2015, 8:89-93

Published Date: 9 February 2015

Nanocomplexation of thrombin with cationic amylose derivative for improved stability and hemostatic efficacy

Zhuang B, Li Z, Pang J, Li W, Huang P, Wang J, Zhou Y, Lin Q, Zhou Q, Ye X, Ye H, Liu Y, Zhang LM, Chen R

International Journal of Nanomedicine 2015, 10:939-947

Published Date: 29 January 2015

Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups

Assaad-Khalil SH, Najem R, Sison J, Kitchlew AR, Cho BL, Ueng KC, DiTommaso S, Shete A

Vascular Health and Risk Management 2015, 11:71-78

Published Date: 21 January 2015

Fluorescent magnetic iron oxide nanoparticles for cardiac precursor cell selection from stromal vascular fraction and optimization for magnetic resonance imaging

Verma VK, Kamaraju SR, Kancherla R, Kona LK, Beevi SS, Debnath T, Usha SP, Vadapalli R, Arbab AS, Chelluri LK

International Journal of Nanomedicine 2015, 10:711-726

Published Date: 20 January 2015